Treatment of Corneal Neovascularization Using Anti-VEGF Bevacizumab
نویسندگان
چکیده
منابع مشابه
Treatment of Corneal Neovascularization Using Anti-VEGF Bevacizumab
Purpose. To evaluate antiangiogenic effect of local use of bevacizumab (anti-VEGF antibody) in patients with corneal neovascularization. Methods. Patients were divided into two groups. All patients suffered from some form of corneal neovascularization (NV). Patients in group A received 0.2-0.5 mL of bevacizumab solution subconjunctivally (concentration 25 mg/mL) in a single dose. Group A includ...
متن کاملComparison of the effects of subconjunctival and topical anti-VEGF therapy (bevacizumab) on experimental corneal neovascularization.
PURPOSE To compare the effects of bevacizumab applied either subconjunctivally or topically, in a rat model of corneal neovascularization induced by alkali burn. METHODS The right corneas of 24 Wistar-Albino rats were cauterized with silver nitrate sticks. The rats were divided randomly and equally into three groups: no treatment control (n=8), subconjunctival bevacizumab treatment (n=8), and...
متن کاملRanibizumab Injection for Corneal Neovascularization Refractory to Bevacizumab Treatment
Vascular endothelial growth factor inhibitor is an emerging therapeutic modality for various ocular diseases with neovascularization (NV). However, for corneal NV, controversy remains regarding whether bevacizumab or ranibizumab is superior. A 32-year-old female diagnosed with herpetic keratoconjunctivitis with refractory corneal NV despite two previous subconjunctival and intrastromal bevacizu...
متن کاملTopical bevacizumab therapy for corneal neovascularization.
Angiogenesis has been defined as the formation of new blood vessels from preexisting vascular structures. Corneal neovascularization (NV) occurs when the balance between angiogenic and antiangiogenic factors shifts toward angiogenic factors. Vascular endothelial growth factor (VEGF) has been found to be a significant angiogenic factor in corneal NV in human and animal models. Therapy specifical...
متن کاملCorneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin).
Corneal avascularity is necessary for the preservation of optimal vision. The cornea maintains a dynamic balance between pro- and antiangiogenic factors that allows it to remain avascular under normal homeostatic conditions; however, corneal avascularity can be compromised by pathologic conditions that negate the cornea's "angiogenic privilege." The clinical relevance of corneal neovascularizat...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Ophthalmology
سال: 2014
ISSN: 2090-004X,2090-0058
DOI: 10.1155/2014/178132